Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder

PURPOSE: Long-term persistence with pharmacotherapy for overactive bladder (OAB) requires a drug with an early onset of action and good efficacy and tolerability profile. Although antimuscarinics improve OAB symptoms within 1–2 weeks of initiating treatment, adherence after 3 months is relatively po...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:World J Urol
Hlavní autoři: Chapple, Christopher R., Nitti, Victor W., Khullar, Vik, Wyndaele, Jean Jacques, Herschorn, Sender, van Kerrebroeck, Philip, Blauwet, Mary Beth, Siddiqui, Emad
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Berlin Heidelberg 2014
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4236626/
https://ncbi.nlm.nih.gov/pubmed/24458878
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00345-014-1244-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky